Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma

被引:28
作者
Crowely, Maeve P. [1 ]
Quinn, Shane [1 ]
Coleman, Eoin [1 ]
Eustace, Joseph A. [2 ]
Gilligan, Oonagh M. [1 ]
Shea, Susan I. O. [1 ]
机构
[1] Cork Univ Hosp, Dept Haematol, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, HRB Clin Res Facil, Cork, Ireland
关键词
Myeloma; Mgus; Thrombosis; Thromboelastography; VON-WILLEBRAND-FACTOR; DEEP-VEIN THROMBOSIS; FACTOR-VIII; VENOUS THROMBOEMBOLISM; TISSUE FACTOR; TUMOR PROGRESSION; CANCER-PATIENTS; RISK-FACTORS; ANGIOGENESIS; THALIDOMIDE;
D O I
10.1007/s11239-014-1140-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. There is little data with regard to changes in thromboelastography in patients with myeloma or MGUS. The aim of this study was to investigate the differing coagulation profiles of patients of patients with myeloma and MGUS by means of conventional coagulation tests and thromboelastography. Blood was taken by direct venepuncture from patients with myeloma, MGUS and normal controls. Routine coagulation tests were performed in an accredited hospital laboratory. Thromboelastography (TEG(A (R))) was performed as per the manufacturer's protocol. Eight patients were recruited in each group. Patients with myeloma had a significantly lower mean haemoglobin level than patients with MGUS or normal controls (p < 0.001). Pateints with myeloma had a significantly more prolonged mean prothrombin time than normal controls (p = 0.018) but not patients with MGUS. Patients with myeloma had significantly higher median D-dimer levels than normal controls (p = 0.025), as did patients with MGUS (p = 0.017). Patients with myeloma had a significantly higher mean factor VIII level than normal controls (p = 0.009) and there was a non-significant trend towards patients with MGUS having higher factor VIII levels than normal controls (p = 0.059). There was no significant difference in thromboelastographic parameters between the three groups. Patients with MGUS appear to have a distinct coagulation profile which is intermediate between patients with myeloma and normal controls.
引用
收藏
页码:245 / 249
页数:5
相关论文
共 31 条
[21]   Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment [J].
Minnema, MC ;
Fijnheer, R ;
De Groot, PG ;
Lokhorst, HM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :445-449
[22]  
ODonnell J, 1997, THROMB HAEMOSTASIS, V77, P825
[23]   Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma [J].
Palumbo, A. ;
Rajkumar, S. V. ;
Dimopoulos, M. A. ;
Richardson, P. G. ;
Miguel, J. San ;
Barlogie, B. ;
Harousseau, J. ;
Zonder, J. A. ;
Cavo, M. ;
Zangari, M. ;
Attal, M. ;
Belch, A. ;
Knop, S. ;
Joshua, D. ;
Sezer, O. ;
Ludwig, H. ;
Vesole, D. ;
Blade, J. ;
Kyle, R. ;
Westin, J. ;
Weber, D. ;
Bringhen, S. ;
Niesvizky, R. ;
Waage, A. ;
von Lilienfeld-Toal, M. ;
Lonial, S. ;
Morgan, G. J. ;
Orlowski, R. Z. ;
Shimizu, K. ;
Anderson, K. C. ;
Boccadoro, M. ;
Durie, B. G. ;
Sonneveld, P. ;
Hussein, M. A. .
LEUKEMIA, 2008, 22 (02) :414-423
[24]   Thalidomide for treatment of multiple myeloma: 10 years later [J].
Palumbo, Antonio ;
Facon, Thierry ;
Sonneveld, Pieter ;
Blade, Joan ;
Offidani, Massimo ;
Gay, Francesca ;
Moreau, Philippe ;
Waage, Anders ;
Spencer, Andrew ;
Ludwig, Heinz ;
Boccadoro, Mario ;
Harousseau, Jean-Luc .
BLOOD, 2008, 111 (08) :3968-3977
[25]   Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia [J].
Pandey, S. ;
Post, S. R. ;
Alapat, D. V. ;
Smock, K. J. ;
Post, G. R. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2013, 35 (04) :421-427
[26]  
Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111
[27]   The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: Tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer [J].
Rickles, FR ;
Shoji, M ;
Abe, K .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (02) :145-150
[28]   ELEVATION OF FACTOR VIII (ANTIHEMOPHILIC FACTOR) DURING PREGNANCY IN NORMAL PERSONS AND IN PATIENT WITH VON WILLEBRANDS DISEASE [J].
STRAUSS, HS ;
DIAMOND, LK .
NEW ENGLAND JOURNAL OF MEDICINE, 1963, 269 (23) :1251-+
[29]   Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis [J].
Trelinski, Jacek ;
Misiewicz, Malgorzata ;
Robak, Marta ;
Smolewski, Piotr ;
Chojnowski, Krzysztof .
THROMBOSIS RESEARCH, 2014, 133 (04) :667-670
[30]   Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis [J].
Yu, JL ;
May, L ;
Lhotak, V ;
Shahrzad, S ;
Shirasawa, S ;
Weitz, JI ;
Coomber, BL ;
Mackman, N ;
Rak, JW .
BLOOD, 2005, 105 (04) :1734-1741